+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pulmonary Arterial Hypertension Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2025

  • ID: 5020221
  • Report
  • March 2020
  • Region: Global
  • 100 pages
  • Infinium Global Research
UP TO OFF
until Dec 31st 2020
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer Inc.
  • Steady Med Ltd.
  • MORE
The report on the global pulmonary arterial hypertension market provides qualitative and quantitative analysis for the period from 2017 to 2025. The report predicts the global pulmonary arterial hypertension market to grow with a CAGR of 5.8% over the forecast period from 2019-2025. The study on pulmonary arterial hypertension market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.

The report on pulmonary arterial hypertension market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global pulmonary arterial hypertension market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global pulmonary arterial hypertension market over the period of 2017 to 2025. Further, Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers
  • Favorable government initiatives for pulmonary arterial hypertension treatment drug
  • Changing lifestyle such as excessive alcohol consumption, lack of physical activity, smoking, and consumption of fast food
2) Restraints
  • High cost of diagnosis and treatment and side effects associated with the drugs
3) Opportunities
  • Technological advancements for new product development and new pathways for better treatment
Research Methodology

A) Primary Research
The primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include
1. Key Opinion Leaders
2. Internal and External subject matter experts
3. Professionals and participants from the industry

The primary research respondents typically include
1. Executives working with leading companies in the market under review
2. Product/brand/marketing managers
3. CXO level executives
4. Regional/zonal/ country managers
5. Vice President level executives.

B) Secondary Research
Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. Each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include
1. Company reports and publications
2. Government/institutional publications
3. Trade and associations journals
4. Databases such as WTO, OECD, World Bank, and among others.
5. Websites and publications by research agencies

Segment Covered
The global pulmonary arterial hypertension market is segmented on the basis of drug type, and sales channel.

The Global Pulmonary Arterial Hypertension Market by Drug Type
  • Endothelin Receptor Antagonists (ERAs)
  • Bosentan
  • Ambrisentan
  • Macitentan
  • Others
  • Prostacyclin and Prostacyclin Analogs
  • Epoprostenol
  • Iloprost
  • Treprostinil
  • Others
  • SGC Stimulators
  • PDE-5 Dipsticks
  • Sildenafil
  • Tadalafil
The Global Pulmonary Arterial Hypertension Market by Sales Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
Company Profiles
The companies covered in the report include
  • GlaxoSmithKline plc
  • Actelion Pharmaceuticals Ltd
  • United Therapeutics Corporation
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Eli Lilly and Company
  • Steady Med Ltd.
  • Teva Pharmaceuticals Inc.
  • Actelion Pharmaceuticals, Ltd.
  • Novartis International AG
What does this report deliver?
1. Comprehensive analysis of the global as well as regional markets of the pulmonary arterial hypertension market.
2. Complete coverage of all the segments in the pulmonary arterial hypertension market to analyze the trends, developments in the global market and forecast of market size up to 2025.
3. Comprehensive analysis of the companies operating in the global pulmonary arterial hypertension market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.
4. Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Novartis International AG
  • Pfizer Inc.
  • Steady Med Ltd.
  • MORE
1. Preface
1.1. Report Description
1.2. Research Methods
1.3. Research Approaches

2. Executive Summary
2.1. Pulmonary Arterial Hypertension Market Highlights
2.2. Pulmonary Arterial Hypertension Market Projection
2.3. Pulmonary Arterial Hypertension Market Regional Highlights

3. Global Pulmonary Arterial Hypertension Market Overview
3.1. Introduction
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. Porter's Five Forces Analysis
3.4. Growth Matrix Analysis
3.4.1. Growth Matrix Analysis by Drug Type
3.4.2. Growth Matrix Analysis by Sales Channel
3.4.3. Growth Matrix Analysis by Region
3.5. Value Chain Analysis of Pulmonary Arterial Hypertension Market

4. Pulmonary Arterial Hypertension Market Macro Indicator Analysis

5. Global Pulmonary Arterial Hypertension Market by Drug Type
5.1. Endothelin Receptor Antagonists (ERAs)
5.1.1. Bosentan
5.1.2. Ambrisentan
5.1.3. Macitentan
5.1.4. Others
5.2. Prostacyclin and Prostacyclin Analogs
5.2.1. Epoprostenol
5.2.2. Iloprost
5.2.3. Treprostinil
5.2.4. Others
5.3. SGC Stimulators
5.4. PDE-5 Dipsticks
5.4.1. Sildenafil
5.4.2. Tadalafil

6. Global Pulmonary Arterial Hypertension Market by Sales Channel
6.1. Hospital Pharmacy
6.2. Retail Pharmacy
6.3. Online Pharmacy

7. Global Pulmonary Arterial Hypertension Market by Region 2019-2025
7.1. North America
7.1.1. North America Pulmonary Arterial Hypertension Market by Drug Type
7.1.2. North America Pulmonary Arterial Hypertension Market by Sales Channel
7.1.3. North America Pulmonary Arterial Hypertension Market by Country
7.2. Europe
7.2.1. Europe Pulmonary Arterial Hypertension Market by Drug Type
7.2.2. Europe Pulmonary Arterial Hypertension Market by Sales Channel
7.2.3. Europe Pulmonary Arterial Hypertension Market by Country
7.3. Asia-Pacific
7.3.1. Asia-Pacific Pulmonary Arterial Hypertension Market by Drug Type
7.3.2. Asia-Pacific Pulmonary Arterial Hypertension Market by Sales Channel
7.3.3. Asia-Pacific Pulmonary Arterial Hypertension Market by Country
7.4. RoW
7.4.1. RoW Pulmonary Arterial Hypertension Market by Drug Type
7.4.2. RoW Pulmonary Arterial Hypertension Market by Sales Channel
7.4.3. RoW Pulmonary Arterial Hypertension Market by Sub-region

8. Company Profiles and Competitive Landscape
8.1. Competitive Landscape in the Global Pulmonary Arterial Hypertension Market
8.2. Companies Profiled
8.2.1. GlaxoSmithKline plc
8.2.2. Actelion Pharmaceuticals Ltd
8.2.3. United Therapeutics Corporation
8.2.4. Pfizer Inc.
8.2.5. Gilead Sciences, Inc.
8.2.6. Eli Lilly and Company
8.2.7. Steady Med Ltd.
8.2.8. Teva Pharmaceuticals Inc.
8.2.9. Actelion Pharmaceuticals, Ltd.
8.2.10. Novartis International AG

9. Appendix
9.1. Primary Research Findings and Questionnaire
Note: Product cover images may vary from those shown
3 of 3
  • GlaxoSmithKline plc
  • Actelion Pharmaceuticals Ltd
  • United Therapeutics Corporation
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Eli Lilly and Company
  • Steady Med Ltd.
  • Teva Pharmaceuticals Inc.
  • Actelion Pharmaceuticals, Ltd.
  • Novartis International AG
Note: Product cover images may vary from those shown
Adroll
adroll